Anastasia Lubarsky
TBI is a leading cause of death and disability. Neuroinflammation drives secondary injury and risk of PTE. IL-6, a key inflammatory mediator, is linked to worse outcomes and may be modifiable with existing drugs. Dysregulation of its signalling pathways may worsen inflammation, yet its temporal dynamics and cellular mechanisms remain unclear.
ELISA was used to quantify IL-6, soluble IL-6 receptor (sIL-6R), and soluble glycoprotein 130 (sgp130) concentrations in two European studies, CENTER-TBI and ICON-TBI, to determine the temporal dynamics of IL-6 signalling and its relationship to PTE.
In ICON-TBI (199 plasma samples, n=48; days 2, 3, 5, 7, 42, 365 post-TBI), mediator temporal dynamics were profiled. IL-6 peaked within 3 days and gradually declined but remained elevated versus controls. sIL-6R and sgp130 dipped during the acute phase, peaking at day 42, suggesting a delayed compensatory response to IL-6.
In CENTER-TBI, IL-6 were consistently higher in PTE than non-PTE patients at both time points (Acute timepoint: median = 106 [CI 126.7-226.8] vs 37.65 [CI 58.1-148.1] pg/ml, p < 0.0001). Remarkably, serum IL-6 concentrations alone predicted PTE risk better than models with clinical risk factors for PTE, highlighting its utility as a biomarker.
Our data established the temporal profiles of IL6, sIL-6R, and sgp130 post-TBI, providing insight into IL-6 signalling and inflammation. We identify IL6 as a predictive biomarker for PTE, indicating its potential role in PTE pathogenesis and its clinical relevance.